Skip to Content
MoleculesMolecules
  • Article
  • Open Access

21 November 2026

14 Pages

Intranasal Immunization with an E. coli-Expressed Omicron BA.5 RBD Elicits Systemic and Mucosal Immunity in Mice

,
,
,
and
1
Department of Biotechnology and Life Science, Faculty of Engineering, Tokyo University of Agriculture and Technology, Nakamachi 2-24-16, Koganei 184-8588, Tokyo, Japan
2
Institute of Global Innovation Research, Tokyo University of Agriculture and Technology, Fuchu 183-8538, Tokyo, Japan
3
Department of Biochemistry and Molecular Biology, Faculty of Biological Sciences, University of Chittagong, Chittagong 4331, Bangladesh
4
Center for Infectious Disease Epidemiology and Prevention Research, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai-Cho, Fuchu 183-8509, Tokyo, Japan
Molecules2026, 31(23), 4243;https://doi.org/10.3390/molecules31234243 
(registering DOI)
This article belongs to the Special Issue Peptide and Protein Folding

Abstract

SARS-CoV-2 infection occurs mainly through the respiratory tract; therefore, intranasal immunization represents a promising strategy for eliciting both systemic and mucosal immunity. In this study, we characterized an E. coli-expressed, non-glycosylated Omicron BA.5 receptor-binding domain (RBD) and evaluated its immunogenicity in mice using subcutaneous (s.c.), intranasal (i.n.), and heterologous s.c. prime–i.n. boost (s.c.-i.n.) immunization regimens. Consistent with our previous finding that s.c. immunization induces systemic anti-RBD IgG responses, three s.c. immunizations induced high systemic anti-RBD IgG responses with detectable IgG subclass responses, but no anti-RBD IgA was detected in bronchoalveolar lavage fluid (BAL). In contrast, three-course intranasal immunization (i.n. ×3) and s.c.-i.n. regimens induced systemic anti-RBD IgG and BAL IgA responses with neutralizing activity against SARS-CoV-2 Omicron BA.5 pseudovirus. Altogether, our data suggest that both intranasal and heterologous immunization with an E. coli-expressed non-glycosylated Omicron RBD induces systemic and mucosal antibody responses. These results support further investigation of this antigen for intranasal and heterologous prime-boost vaccination strategies.

Article Metrics

Citations

Article Access Statistics

Article metric data becomes available approximately 24 hours after publication online.